I doubt the reporter had an in depth understanding on what she wrote. Based on the news, this should not be "block the action of a particular gene". Current tablet therapies only targets BRAF and MEK protein mutation, nothing to do with gene silencing or up to that level using RNAi.
So the treatment has nothing to do with gene, and do not go after lymphangiogenesis, something that midkine aim to do.
Ann: Nature Paper MK in Melanoma, page-50
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.8¢ | $4.315K | 539.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1111500 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 598285 | 2 |
View Market Depth
| Last trade - 11.56am 18/07/2024 (20 minute delay) ? |
| AN1 (ASX) Chart |